Immunomodulatory Therapy for Oncology Clinicians
Source: Immunotherapy for Practicing Clinicians

Module

In this interactive CME-certified activity, Charles G. Drake, MD, PhD, provides an overview of the use of immunomodulatory agents in the treatment of patients with cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Utilize immunotherapies appropriately for the treatment of selected patients with cancer
  • Manage the adverse effects associated with immunotherapies used to treat cancer
  • Discuss clinical trials evaluating novel immunomodulatory agents with appropriate patients

Topics covered include:

  • Introduction to Immunomodulatory Approaches for Cancer Treatment
  • Vaccine Immunotherapy for Prostate Cancer
  • Blocking the Immune Checkpoint Molecule CTLA-4
  • Programmed Death 1: An Immune Checkpoint Molecule Important in Renal Cell Carcinoma, Melanoma, and NSCLC
  • Combining Immune Checkpoint Blockade With Conventional Chemotherapy in Lung Cancer
  • Combined Immune Checkpoint Blockade: The Future of Immunotherapy?
 

Faculty

  • Charles G. Drake
    MD, PhD

Credit Information

  • Release Date:
    July 10, 2012
  • Expiration Date:
    July 09, 2013
  • Physicians:
    maximum of 0.75 AMA PRA Category 1 Credits
  • Does Denosumab Confer a Survival Benefit for Lung Cancer Patients With Bone Metastases?

    H. Jack West MD - 1/11/2013    2 comments / Last Comment: 10/14/2013
    Bone-directed therapy is an important aspect of care for patients with advanced lung cancer and skeletal metastases; but does denosumab offer a survival benefit?
  • Targeting MEK in NRAS-Mutant Melanoma: A Promising Therapeutic Strategy?

    Keith T. Flaherty MD - 12/17/2012    1 comment / Last Comment: 12/18/2012
    Patients with NRAS-mutant melanoma have few treatment options. In this post, I review recent research suggesting that agents targeting MEK signaling in the RAS cascade could potentially be as effective in this setting as BRAF inhibitors are in BRAF-mutant melanoma.
  • How I Use Abiraterone in Metastatic CRPC: A Case Illustration

    H. Jack West MD - 3/22/2013    18 comments / Last Comment: 8/7/2013
    For patients who are poor candidates for chemotherapy or disinclined to pursue it, abiraterone makes a lot of sense. In this post, I describe my approach to a 77-year-old patient who is fit but, nevertheless, wary of receiving chemotherapy
  • Antigen-Based Vaccines: Will This Provide an Improvement in Standard of Care for Patients With Lung Cancer?

    Corey J. Langer MD, FACP - 3/27/2013    2 comments / Last Comment: 6/8/2013
    Although promising, several unanswered questions must be addressed to make the use of vaccines in the treatment of lung cancer a reality.
  • Adding Radium-223 to Our Current Treatment Paradigm for Metastatic CRPC: My Thoughts

    David I. Quinn MD, PhD - 5/22/2013    6 comments / Last Comment: 8/29/2013
    Radium-223 extended survival in CRPC with minimal toxicity in the ALSYMPCA randomized phase III trial. So when and how should this new therapeutic agent be used in our practices?